|
Market Closed -
OTC Markets
11:44:54 2026-06-02 EDT
|
5-day change | 1st Jan Change | ||
| 0.008000 USD | -39.39% |
|
+8.11% | -10.11% |
| 05-28 | Pharmadrug Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-29 | Pharmadrug Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: Pharmadrug Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 15.76 | 11.93 | 5.334 | 4.809 | 1.077 | 1.624 |
| Change | - | -24.31% | -55.28% | -9.85% | -77.6% | 50.7% |
| Enterprise Value (EV) 1 | 12.48 | 11.5 | 6.428 | 6.153 | 2.351 | 3.124 |
| Change | - | -7.87% | -44.1% | -4.28% | -61.79% | 32.88% |
| P/E | -2.18x | -2.06x | -0.59x | -0.24x | -1.31x | -4.23x |
| PBR | 2.07x | 0.71x | 0.6x | -2.84x | -0.77x | -0.92x |
| PEG | - | 0x | -0x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 23.1x | 24.1x | - | - | - | - |
| EV / Revenue | 18.3x | 23.2x | - | - | - | - |
| EV / EBITDA | -4.91x | -3x | -3.62x | -4.61x | -4.03x | -19.9x |
| EV / EBIT | -3.29x | -2.28x | -2.73x | -4.52x | -3.71x | -15.1x |
| EV / FCF | -10.2x | -7.4x | -6.3x | 3.6x | -3.5x | -7.23x |
| FCF Yield | -9.82% | -13.5% | -15.9% | 27.7% | -28.6% | -13.8% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.2565 | -0.1189 | -0.179 | -0.234 | -0.007632 | -0.003545 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.6837 | 0.495 | - | - | - | - |
| EBITDA 1 | -2.544 | -3.828 | -1.777 | -1.335 | -0.5833 | -0.1568 |
| EBIT 1 | -3.799 | -5.047 | -2.356 | -1.361 | -0.6336 | -0.207 |
| Net income 1 | -5.219 | -5.626 | -8.876 | -13.2 | -0.7933 | -0.3834 |
| Net Debt 1 | -3.279 | -0.429 | 1.093 | 1.344 | 1.274 | 1.501 |
| Reference price 2 | 0.5600 | 0.2450 | 0.1050 | 0.0550 | 0.0100 | 0.0150 |
| Nbr of stocks (in thousands) | 28,144 | 48,688 | 50,804 | 87,437 | 107,734 | 108,234 |
| Announcement Date | 4/30/21 | 5/3/22 | 5/12/23 | 4/30/24 | 5/1/25 | 4/30/26 |
1CAD in Million2CAD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 23.09x | 0.25x | 14.48x | 0.4% | 105B | |
| 25.9x | 0.22x | 13.27x | 0.87% | 55.88B | |
| 46.55x | 3.28x | 30.51x | 1.33% | 24.12B | |
| 11.74x | 0.2x | 5x | 2.59% | 8.28B | |
| 13.45x | 1.02x | 8.25x | 2.51% | 7.75B | |
| 5.9x | 0.1x | 2.71x | 5.02% | 6.69B | |
| 9.07x | 1.7x | 5.44x | 3.62% | 6.16B | |
| 24.92x | 1.12x | 13.8x | 3.13% | 5.01B | |
| 10.96x | 0.12x | 4.5x | 4.12% | 3.75B | |
| Average | 19.06x | 0.89x | 10.88x | 2.62% | 24.75B | |
| Weighted average by Cap. | 24.51x | 0.65x | 14.56x | 1.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PHRX Stock
- LMLLF Stock
- Valuation Pharmadrug Inc.
Select your edition
All financial news and data tailored to specific country editions
